Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
The company abandons TNG908, but is still all in on the troubled target.
Reports of Arc-10's failure are greatly exaggerated, the company argues.
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
